Eloxx Pharmaceuticals amended its certificate of incorporation to execute a 1-for-11 reverse stock split of common stock, effective upon Delaware filing. The reverse split reduces authorized common shares from 100M to a lower effective count and is typically used to increase share price or meet listing requirements.